Literature DB >> 10633461

Hyperphosphatemia in end-stage renal disease patients: pathophysiological consequences.

F Llach1.   

Abstract

A study of 6407 end-stage renal disease (ESRD) patients has shown that hyperphosphatemia is increasingly important as a risk for mortality. Half of the patients showed serum phosphorus levels of over 6.0 mg/dl; at the same time, an elevated calcium x phosphorus product indicated increased risk of mortality. These observations lead to questions regarding the mechanisms at work in both the observed phenomena and the way in which they affect mortality. To answer these questions, an understanding of the pathophysiological consequences of hyperphosphatemia is necessary.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10633461     DOI: 10.1046/j.1523-1755.1999.07316.x

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  4 in total

1.  The calcimimetic agent KRN 1493 lowers plasma parathyroid hormone and ionized calcium concentrations in patients with chronic renal failure on haemodialysis both on the day of haemodialysis and on the day without haemodialysis.

Authors:  Naro Ohashi; Toshihiko Uematsu; Satoru Nagashima; Mitsutaka Kanamaru; Akashi Togawa; Akira Hishida; Eiji Uchida; Tadao Akizawa; Shozo Koshikawa
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

2.  Parathyroid ultrasonography and bone metabolic profile of patients on dialysis with hyperparathyroidism.

Authors:  Cláudia Ribeiro; Maria Goretti Moreira Guimarães Penido; Milena Maria Moreira Guimarães; Marcelo de Sousa Tavares; Bruno das Neves Souza; Anderson Ferreira Leite; Leonardo Martins Caldeira de Deus; Lucas José de Campos Machado
Journal:  World J Nephrol       Date:  2016-09-06

Review 3.  Calciphylaxis.

Authors:  R V Mathur; J R Shortland; A M el-Nahas
Journal:  Postgrad Med J       Date:  2001-09       Impact factor: 2.401

4.  Suspected systemic calcinosis and calciphylaxis in 5 horses.

Authors:  Jean-Yin Tan; Stephanie J Valberg; Manu M Sebastian; Gordon D Davis; Jenny R Kelly; Lutz S Goehring; Malte M Harland; K Leann Kuebelbeck; Bryan M Waldridge; Joseph C Newton; Johanna M Reimer
Journal:  Can Vet J       Date:  2010-09       Impact factor: 1.008

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.